High-throughput virtual screening of Streptomyces spp. metabolites as antiviral inhibitors against the Nipah virus matrix protein
Graphical Abstract
Display Omitted
References
[1]
Anslyn, E.V., Dougherty, D.A., 2006. Modern physical organic chemistry. University science books.
[2]
A.T. Ayoub, M.A. Elrefaiy, K. Arakawa, Computational prediction of the mode of binding of antitumor lankacidin C to tubulin, ACS Omega 4 (2019) 4461–4471,.
[3]
M.W. Chang, C. Ayeni, S. Breuer, B.E. Torbett, Virtual screening for hiv protease inhibitors: a comparison of AutoDock 4 and VINa, PLoS One 5 (2010),.
[4]
Y. Chang, B.A. Hawkins, J.J. Du, P.W. Groundwater, D.E. Hibbs, F. Lai, A guide to in silico drug design, Pharmaceutics 15 (2022) 49,.
[5]
L.-Y. Chen, X.-Q. Wang, Y.-M. Wang, X. Geng, X.-N. Xu, C. Su, Y.-L. Yang, Y.-J. Tang, F.-W. Bai, X.-Q. Zhao, Genome mining of Streptomyces xinghaiensis NRRL B-24674T for the discovery of the gene cluster involved in anticomplement activities and detection of novel xiamycin analogs, Appl. Microbiol Biotechnol. 102 (2018) 9549–9562,.
[6]
D. Dhakal, J.M. Han, R. Mishra, R.P. Pandey, T.-S. Kim, V. Rayamajhi, H.J. Jung, T. Yamaguchi, J.K. Sohng, Characterization of tailoring steps of nargenicin A1 biosynthesis reveals a novel analogue with anticancer activities, ACS Chem. Biol. 15 (2020) 1370–1380,.
[7]
L.G. Ferreira, R.N. Dos Santos, G. Oliva, A.D. Andricopulo, Molecular docking and structure-based drug design strategies, Molecules 20 (2015) 13384–13421,.
[8]
P. Fu, S. La, J.B. MacMillan, 1,3-oxazin-6-one derivatives and bohemamine-type pyrrolizidine alkaloids from a marine-derived streptomyces spinoverrucosus, J. Nat. Prod. 79 (2016) 455–462,.
[9]
S. Genheden, U. Ryde, The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities, Expert Opin. Drug Discov. 10 (2015) 449–461,.
[10]
J.M. Han, Y.S. Choi, D. Dhakal, J.K. Sohng, H.J. Jung, Novel nargenicin A1 analog Inhibits angiogenesis by downregulating the endothelial VEGF/VEGFR2 signaling and tumoral HIF-1α/VEGF pathway, Biomedicines 8 (2020) 252,.
[11]
N. Hauser, A.C. Gushiken, S. Narayanan, S. Kottilil, J.V. Chua, Evolution of Nipah Virus Infection: Past, Present, and Future Considerations, Trop. Med. Infect. Dis. 6 (2021) 24,.
[12]
D.R. Houston, M.D. Walkinshaw, Consensus docking: improving the reliability of docking in a virtual screening context, J. Chem. Inf. Model. 53 (2013) 384–390,.
[13]
Huey, R., Morris, G.M., Forli, S., 2011. Using AutoDock 4 and Vina with AutoDockTools: A Tutorial. Scripps Research Institute, California, USA.
[14]
R. Izairi, H. Kamberaj, Comparison study of polar and nonpolar contributions to solvation free energy, J. Chem. Inf. Model. 57 (2017) 2539–2553,.
[15]
G. Jiang, Yucheng Zhang, M.M. Powell, P. Zhang, R. Zuo, Yi Zhang, D. Kallifidas, A.M. Tieu, H. Luesch, R. Loria, Y. Ding, High-yield production of herbicidal thaxtomins and thaxtomin analogs in a nonpathogenic streptomyces strain, Appl. Environ. Microbiol 84 (2018),.
[16]
K. Johnson, M. Vu, A.N. Freiberg, Recent advances in combating Nipah virus, Fac. Rev. 10 (2021) 74,.
[17]
W.S. Jung, S.J. Jeong, S.R. Park, C.Y. Choi, B.C. Park, J.W. Park, Y.J. Yoon, Enhanced heterologous production of desosaminyl macrolides and their hydroxylated derivatives by overexpression of the pikD regulatory gene in Streptomyces venezuelae, Appl. Environ. Microbiol 74 (2008) 1972–1979,.
[18]
S. Khoshnood, M. Shirani, A. Dalir, M. Moradi, M.H. Haddadi, N. Sadeghifard, F.S. Birjandi, I. Yashmi, M. Heidary, Antiviral effects of azithromycin: a narrative review, Biomed. Pharmacother. 147 (2022),.
[19]
H. Kinashi, Giant linear plasmids in Streptomyces: a treasure trove of antibiotic biosynthetic clusters, J. Antibiot. (Tokyo) 64 (2011) 19–25,.
[20]
H. Kinashi, E. Mori, A. Hatani, O. Nimi, Isolation and characterization of linear plasmids from lankacidin-producing Streptomyces species., J. Antibiot. (Tokyo) 47 (1994) 1447–1455,.
[21]
D.D. Kulkarni, C. Tosh, G. Venkatesh, D. Senthil Kumar, Nipah virus infection: current scenario, Indian J. Virol. 24 (2013) 398–408,.
[22]
R. Kumari, R. Kumar, Open Source Drug Discovery Consortium, A. Lynn, g_mmpbsa —A GROMACS Tool for High-Throughput MM-PBSA Calculations, J. Chem. Inf. Model. 54 (2014) 1951–1962,.
[23]
S.K. Lam, K.B. Chua, Nipah Virus Encephalitis Outbreak in Malaysia, Clin. Infect. Dis. 34 (2002) S48–S51,.
[24]
L.-T. Lin, W.-C. Hsu, C.-C. Lin, Antiviral Natural Products and Herbal Medicines, J. Tradit. Complement Med 4 (2014) 24–35,.
[25]
C.A. Lipinski, Lead- and drug-like compounds: the rule-of-five revolution, Drug Discov. Today.: Technol. 1 (2004) 337–341,.
[26]
X. Liu, D. Xie, R. Chen, M. Mei, J. Zou, X. Chen, J. Dai, A furantaxane with an unusual 6/8/6/5 ring system and potent tumor MDR reversal activity obtained via microbial transformation, Org. Lett. 14 (2012) 4106–4109,.
[27]
S.P. Luby, The pandemic potential of Nipah virus, Antivir. Res. 100 (2013) 38–43,.
[28]
M.A.B. Macalalad, F.L. Orosco, In silico identification of multi-target inhibitors from medicinal fungal metabolites against the base excision repair pathway proteins of African swine fever virus, RSC Adv. 14 (2024) 10039–10055.
[29]
M.R.A. Mahedi, A. Rawat, F. Rabbi, K.S. Babu, E.S. Tasayco, F.O. Areche, O.V. Pacovilca-Alejo, D.D.C. Flores, S.V. Aguilar, F.L. Orosco, Understanding the global transmission and demographic distribution of Nipah virus (NiV), Res. J. Pharm. Technol. 16 (2023) 3588–3594.
[30]
Y. Mast, W. Wohlleben, Streptogramins - two are better than one!, Int J. Med Microbiol 304 (2014) 44–50,.
[31]
R.K. McLean, S.P. Graham, Vaccine development for nipah virus infection in pigs, Front. Vet. Sci. 6 (2019),.
[32]
E.S. Medina-Magües, J. Lopera-Madrid, M.K. Lo, C.F. Spiropoulou, J.M. Montgomery, L.G. Medina-Magües, C. Salas-Quinchucua, A.P. Jiménez-Mora, J.E. Osorio, Immunogenicity of poxvirus-based vaccines against Nipah virus, Sci. Rep. 13 (2023),.
[33]
J.-Y. Min, Y.J. Jang, Macrolide therapy in respiratory viral infections, Mediat. Inflamm. 2012 (2012),.
[34]
G. Mishra, V. Prajapat, D. Nayak, Advancements in Nipah virus treatment: Analysis of current progress in vaccines, antivirals, and therapeutics, Immunology 171 (2024) 155–169,.
[35]
G.M. Morris, R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, A.J. Olson, AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility, J. Comput. Chem. 30 (2009) 2785–2791,.
[36]
A.F.A. Moumbock, M. Gao, A. Qaseem, J. Li, P.A. Kirchner, B. Ndingkokhar, B.D. Bekono, C.V. Simoben, S.B. Babiaka, Y.I. Malange, F. Sauter, P. Zierep, F. Ntie-Kang, S. Günther, StreptomeDB 3.0: an updated compendium of streptomycetes natural products, Nucleic Acids Res. 49 (2021) D600–D604,.
[37]
M.J. Norris, M.L. Husby, W.B. Kiosses, J. Yin, R. Saxena, L.J. Rennick, A. Heiner, S.S. Harkins, R. Pokhrel, S.L. Schendel, K.M. Hastie, S. Landeras-Bueno, Z.L. Salie, B. Lee, P.P. Chapagain, A. Maisner, W.P. Duprex, R.V. Stahelin, E.O. Saphire, Measles and Nipah virus assembly: specific lipid binding drives matrix polymerization, Sci. Adv. 8 (2022),.
[38]
F.L. Orosco, Breaking the chains: advancements in antiviral strategies to combat Nipah virus infections, Int. J. One Health (2023) 122–133,.
[39]
F.L. Orosco, Advancing the frontiers: revolutionary control and prevention paradigms against Nipah virus, Open Vet. J. 13 (2023) 1056–1070,.
[40]
F. Orosco, From nature’s pharmacy to swine health: harnessing natural compounds against prrsv infection, Slov. Vet. Res. -Print. (2024),.
[41]
N. Palaniappan, B.S. Kim, Y. Sekiyama, H. Osada, K.A. Reynolds, Enhancement and selective production of phoslactomycin B, a protein phosphatase IIa inhibitor, through identification and engineering of the corresponding biosynthetic gene cluster, J. Biol. Chem. 278 (2003) 35552–35557,.
[42]
D. Poddighe, M. Aljofan, Clinical evidences on the antiviral properties of macrolide antibiotics in the COVID-19 era and beyond, Antivir. Chem. Chemother. 28 (2020),.
[43]
S. Prasanna, R. Doerksen, Topological polar surface area: a useful descriptor in 2D-QSAR, Curr. Med. Chem. 16 (2009) 21–41,.
[44]
T. Raihan, M.F. Rabbee, P. Roy, S. Choudhury, K.-H. Baek, A.K. Azad, Microbial metabolites: the emerging hotspot of antiviral compounds as potential candidates to avert viral pandemic alike COVID-19, Front Mol. Biosci. 8 (2021),.
[45]
T. Schwede, J. Kopp, N. Guex, M.C. Peitsch, SWISS-MODEL: an automated protein homology-modeling server, Nucleic Acids Res. 31 (2003) 3381–3385.
[46]
B. Shaker, S. Ahmad, J. Lee, C. Jung, D. Na, In silico methods and tools for drug discovery, Comput. Biol. Med. 137 (2021),.
[47]
N. Suzuki, C.K. Lee, T. Nihira, Y. Yamada, Purification and characterization of virginiamycin M1 reductase from Streptomyces virginiae, Antimicrob. Agents Chemother. 42 (1998) 2985–2988,.
[48]
N. Thakur, D. Bailey, Advances in diagnostics, vaccines and therapeutics for Nipah virus, Microbes Infect. 21 (2019) 278–286,.
[49]
O. Trott, A.J. Olson, AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, J. Comput. Chem. 31 (2010) 455–461,.
[50]
J.B. Tunac, B.D. Graham, W.E. Dobson, Novel antitumor agents CI-920, PD 113,270 and PD 113,271. I. Taxonomy, fermentation and biological properties, J. Antibiot. (Tokyo) 36 (1983) 1595–1600,.
[51]
M.S. Valdés-Tresanco, M.E. Valdés-Tresanco, P.A. Valiente, E. Moreno, gmx_MMPBSA: a new tool to perform end-state free energy calculations with GROMACS, J. Chem. Theory Comput. 17 (2021) 6281–6291,.
[52]
K. Vanommeslaeghe, A.D. MacKerell, Automation of the CHARMM general force field (CGenFF) I: bond perception and atom typing, J. Chem. Inf. Model. 52 (2012) 3144–3154,.
[53]
K. Vanommeslaeghe, E.P. Raman, A.D. MacKerell, Automation of the CHARMM general force field (CGenFF) II: assignment of bonded parameters and partial atomic charges, J. Chem. Inf. Model. 52 (2012) 3155–3168,.
[54]
J. Wakefield, H.M. Hassan, M. Jaspars, R. Ebel, M.E. Rateb, Dual induction of new microbial secondary metabolites by fungal bacterial co-cultivation, Front Microbiol 8 (2017) 1284,.
[55]
M. Winn, D. Francis, J. Micklefield, De novo biosynthesis of “non-natural” thaxtomin phytotoxins, Angew. Chem. Int Ed. Engl. 57 (2018) 6830–6833,.
[56]
World Health Organization, 2018. Nipah virus infection [WWW Document]. URL https://www.who.int/health-topics/nipah-virus-infection (accessed 2.19.24).
[57]
G. Xiong, Z. Wu, J. Yi, L. Fu, Z. Yang, C. Hsieh, M. Yin, X. Zeng, C. Wu, A. Lu, X. Chen, T. Hou, D. Cao, ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties, Nucleic Acids Res 49 (2021) W5–W14,.
[58]
R. Zirkle, J.M. Ligon, I. Molnár, Heterologous production of the antifungal polyketide antibiotic soraphen A of Sorangium cellulosum So ce26 in Streptomyces lividans, Microbiol. (Read. ) 150 (2004) 2761–2774,.
Index Terms
- High-throughput virtual screening of Streptomyces spp. metabolites as antiviral inhibitors against the Nipah virus matrix protein
Index terms have been assigned to the content through auto-classification.
Recommendations
Structure-based virtual screening of influenza virus RNA polymerase inhibitors from natural compounds: Molecular dynamics simulation and MM-GBSA calculation
Graphical abstractDisplay Omitted
Highlights- Structure-based virtual screening was performed to discover influenza virus polymerase inhibitors.
AbstractThe resistances of matrix protein 2 (M2) protein inhibitors and neuraminidase inhibitors for influenza virus have attracted much attention and there is an urgent need for new drug. The antiviral drugs that selectively act on RNA ...
Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations
Graphical abstractThe virtual screening, molecular docking, ADMET prediction and molecular dynamics simulations were performed on Asinex database to find the novel compounds against PI3Kδ, which were demonstrated as the following flow chart:
...Highlights- Phosphoinositide-3-kinase Delta (PI3Kδ) is a well-validated target for anticancer drug design and development.
Abstract BackgroundPhosphoinositide-3-kinase Delta (PI3Kδ) plays a key role in B-cell signal transduction and inhibition of PI3Kδ is confirmed to have clinical benefit in certain types of activation of B-cell malignancies. Virtual ...
Integrated computational approaches for designing potent pyrimidine-based CDK9 inhibitors: 3D-QSAR, docking, and molecular dynamics simulations
AbstractCDK9 is an emerging target for the development of anticancer drugs. The development of CDK9 inhibitors with significant potency had consistently posed a formidable challenge. In the current research, a number of computational methodologies, such ...
Graphical AbstractDisplay Omitted
Highlights- Employing a comprehensive computational strategy encompassing 3D-QSAR, molecular docking, fingerprint analysis, MD simulations, MMGB/PBSA, and ADMET studies, the research uncovers the binding mechanism of pyrimidine derivatives against ...
Comments
Please enable JavaScript to view thecomments powered by Disqus.Information & Contributors
Information
Published In
Elsevier Ltd.
Publisher
Elsevier Science Publishers B. V.
Netherlands
Publication History
Published: 21 November 2024
Author Tags
Author Tags
Qualifiers
- Research-article
Contributors
Other Metrics
Bibliometrics & Citations
Bibliometrics
Article Metrics
- 0Total Citations
- 0Total Downloads
- Downloads (Last 12 months)0
- Downloads (Last 6 weeks)0
Reflects downloads up to 27 Nov 2024
Other Metrics
Citations
View Options
View options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Sign in